Topical Ruxolitinib Versus Tacrolimus With Excimer Laser for Localized Vitiligo
Key facts
- Who runs it
- Kafrelsheikh University
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Enrolling by invitation
- People taking part
- 40 people, planned
- Started
- 1 Jul 2026
- Expected to end
- 1 Jan 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Tacrolimus 0.1% ointment
- Ruxolitinib 1.5% cream
- 308-nm excimer laser
- Record updated
- 2 November 2026
Who can take part
- Age
- 12 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Stable localized non-segmental facial vitiligo
- Age 12 years or older
- Nonsmoker
- No vitiligo treatment during the preceding 6 months
- Selected lesion surface area less than 20 cm2
Who cannot take part
- Vitiligo treatment within the previous 6 months
- Diabetes mellitus
- Collagen vascular disease or other autoimmune disease
- Relevant systemic illness, other skin disease, drug allergy, or contraindication identified during screening
- Pregnancy or lactation
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This randomized comparative study will evaluate the efficacy and safety of topical ruxolitinib 1.5% cream compared with topical tacrolimus 0.1% ointment, each combined with 308-nm excimer laser therapy, in patients aged 12 years or older with stable localized non-segmental facial vitiligo. Forty participants will be randomly assigned in a 1:1 ratio to receive one of the topical treatments twice daily for 24 weeks plus excimer laser treatment. Clinical, dermoscopic, patient-reported, and histopathological outcomes will be assessed before and after treatment, with follow-up for recurrence.
The 2 groups in the trial
- Tacrolimus plus excimer laserExisting treatment, for comparison
Tacrolimus 0.1% ointment applied twice daily for 24 weeks, plus 10 sessions of 308-nm excimer laser therapy administered twice weekly.
Treatment: Tacrolimus 0.1% ointment and 308-nm excimer laser
- Ruxolitinib plus excimer laserTreatment being tested
Ruxolitinib 1.5% cream twice daily for 24 weeks plus 10 sessions of 308-nm excimer laser therapy, twice weekly.
Treatment: Ruxolitinib 1.5% cream and 308-nm excimer laser
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Clinical and Histopathological Evaluation of Excimer Laser With Topical Ruxolitinib 1.5% or Tacrolimus 0.1% in Localized Vitiligo: A Randomized Comparative Study
- Record updated
- 2 November 2026